MR-guided Pre-operative RT in Gastric Cancer
Study Details
Study Description
Brief Summary
Gastric cancer is a global health issue as the world's fifth most common malignancy and third leading cause of cancer mortality, respectively. Preoperative radiation therapy may improve overall survival (OS) but is seldom used. There is precedent for preoperative chemoradiation, as it is the standard of care for esophageal and gastroesophageal junction tumors. However, reluctance of physicians to prescribe preoperative radiation therapy in gastric cancer may be due to the large treatment fields necessary to account for stomach motion. MR guided radiation therapy (MRgRT) may permit decreased field sizes and more accurate dose delivery. In traditional CT based radiation delivery the same radiation plan is delivered each day without assessment of inter-fraction or intra-fraction motion. MRgRT permits the physician to contour the unique anatomy daily to generate a new plan to account for day to day organ motion. Real-time MR imaging is also used during the treatment so that radiation is only delivered when the tumor is within the pre-specified target area. Thus, MRgRT may overcome traditional barriers of radiation delivery in gastric cancer and improve oncologic outcomes.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Preoperative MR-guided Radiation Therapy Radiotherapy will consist of five fractions, delivered once daily, to a total dose of 25 Gy at 5 Gy per fraction. The clinical target volume will include the entire stomach and locoregional lymph nodes. Radiation must be delivered with MR guided radiation therapy (MRgRT) and daily adaptive planning. The stomach and OARs must be redrawn each day for the adaptive plan. Plans should be adapted to meet OAR constraints or improve coverage as needed for each day's unique anatomy Chemotherapy will be given as per standard of care. It should begin 2 to 4 weeks after completion of radiotherapy and will consist of CAPOX (capecitabine/oxaliplatin) for 5 cycles. Standard of care gastrectomy or esophagogastrectomy within 2-4 weeks following completion of chemotherapy All stage II-III patients should receive 3 cycles of CAPOX postoperatively for a total of 8 cycles of CAPOX. Postoperative CAPOX should start within 3 months of surgery. |
Radiation: MR guided radiation therapy
-Image-based treatment planning and intensity modulated radiotherapy (IMRT) is permitted.
Other Names:
Procedure: Blood for ctDNA
-Prior to start of radiation, after the completion of radiation therapy and prior to starting chemotherapy (2-4 weeks after radiation completion), at the completion of chemotherapy and prior to surgery (2-4 weeks after chemotherapy completion), and 6 months after surgery
|
Outcome Measures
Primary Outcome Measures
- Complete pathologic response (pCR - primary and nodal) rate [At the time of surgery (approximately 20 weeks)]
-pCR: no pathological signs of cancer
Secondary Outcome Measures
- Average percentage difference in dose to nearby organs at risk (OARs) due to variation in OAR position [Completion of radiation therapy (up to 2 weeks)]
- Local control rate [1 year]
-Local control from the time of gastrectomy
- Rate of grade 3 or greater toxicity as defined by CTCAE version 5.0 [From baseline through 12 months after the end of treatment (approximately 73 weeks)]
- Overall survival [1 year]
-Overall survival from registration on trial
- Average percent difference in coverage of planning target volume (PTV) by 95% isodose line [Completion of radiation therapy (up to 2 weeks)]
- Disease-free survival [1 year]
-Disease free means no locoregional and distant recurrence
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Newly diagnosed histologically or cytologically gastric adenocarcinoma. (Siewert III acceptable: the bulk of tumor should be in stomach; gastric tumors with extension to the gastroesophageal junction are permitted.) Patients with T1-T2N1-2 and T3N0-2 disease are eligible (stage I-III). Patients with T1-2N0, N3, T4, or M1 disease are not eligible.
-
T-stage defined by EUS. Must have had CT of the chest/abdomen/pelvis with contrast.
-
Medically eligible to receive CAPOX chemotherapy
-
At least 19 years of age
-
ECOG performance status ≤ 2
Normal bone marrow and organ function as defined below:
-
Absolute neutrophil count ≥ 1,500 cells/mm3
-
Platelets ≥ 100,000 cells/mm3
-
Hemoglobin > 9 g/dL
-
Creatinine clearance > 50 mL/min
-
The effects of the various chemotherapy agents used in this study on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and one month after completion of the study
-
Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Exclusion Criteria:
-
Prior surgery, radiation, or chemotherapy for gastric or esophageal cancer.
-
Prior surgery to the esophagus or stomach.
-
Siewert I-II GE junction tumor
-
Any active malignancy within 2 years that may alter the course of gastric cancer. (Apparently cured localized malignancy or advanced, but indolent malignancy with significantly more favorable prognosis are allowed).
-
Currently receiving any other investigational agents.
-
Metastatic disease, including gross peritoneal carcinoma
-
Presence of ascites
-
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabine, oxaliplatin, or other agents used in the study.
-
Contraindications to MRI (e.g., non-compatible implantable device or metallic foreign bodies).
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, diabetes, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
-
Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
-
Patients with HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended. Recommend exclusion of specific ART agents based on predicted drug-drug interactions (i.e. for sensitive CYP3A4 substrates, concurrent strong CYP3A4 inhibitors (ritonavir and cobicistat) or inducers (efavirenz) should be contraindicated).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Washington University School of Medicine | Saint Louis | Missouri | United States | 63110 |
| 2 | Seoul National University Hospital | Seoul | Korea, Republic of |
Sponsors and Collaborators
- Washington University School of Medicine
- Viewray Inc.
Investigators
- Principal Investigator: Hyun Kim, M.D., Washington University School of Medicine
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 201911059